We use cookies for a better user experience. Read our Privacy Policy

I Agree

Nonalcoholic Steatohepatitis Therapeutics Market

Nonalcoholic Steatohepatitis Therapeutics Market (Drug Type: Obeticholic Acid (OCA), Aramchol (Arachidyl Amido Cholanoic Acid), Saroglitazar, and Elafibranor) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Nonalcoholic Steatohepatitis Therapeutics Market Outlook 2031

  • The global nonalcoholic steatohepatitis therapeutics market was valued at US$ 10.1 Bn in 2021
  • It is estimated to grow at a CAGR of 13.6% from 2022 to 2031
  • The global nonalcoholic steatohepatitis therapeutics market is expected to surpass value of US$ 20.2 Bn by the end of 2031

Analysts’ Viewpoint on Global Nonalcoholic Steatohepatitis Therapeutics Market Scenario

As there is no FDA-approved drug to treat nonalcoholic steatohepatitis, pharmaceutical companies and market stakeholders are expected to launch pipeline drugs to cure this silent liver disease. The global nonalcoholic steatohepatitis therapeutics market is driven by increase in global prevalence rate of diabetic and obesity, along with rise in awareness about the treatments and drugs available for the same. Moreover, in order to boost credibility credentials, manufacturers are engaging in clinical trials of Elafibranor and various other drugs that help in reducing fat percentage in liver. Market stakeholders should focus on mergers & acquisitions and research collaborations with other companies to launch innovative products for the effective treatment of nonalcoholic steatohepatitis in the upcoming years.

Overview of Global Nonalcoholic Steatohepatitis Therapeutics Market

Nonalcoholic fatty liver disease (NAFLD) is a disorder categorized by excess fat in the liver of people who drink little to no alcohol. No direct cause has yet been identified; however, obesity and insulin resistance are believed to play major roles. Most often, NAFLD goes relatively undetected, as a liver can remain fatty without obstructing its functions.

NAFLD can progress into a far more severe condition known as nonalcoholic steatohepatitis (NASH), a disease characterized by inflammation and irreversible cell death. NASH is a disease that advances over time. Over a period of ten years, up to 20% of patients with NASH develop cirrhosis of the liver, and 10% succumb from the disease.

Presently, NASH is one of the leading causes of liver transplants in the U.S., with a considerable proportion of the general population currently suffering from the disease. NAFLD and NASH are both closely related to diabetes and obesity, and together are considered the leading cause of liver disease in countries in the West. Hence, there is an urgent need of effective treatment options for these diseases. This is expected to propel the nonalcoholic steatohepatitis therapeutics market over the next years.

Request a sample to get extensive insights into the Nonalcoholic Steatohepatitis Therapeutics Market

Surge in Prevalence of Non-alcoholic Steatohepatitis Disease Globally

Nonalcoholic steatohepatitis is a type of liver disease diagnosed in people who are non-alcoholic or consume alcohol in very low amount. Nonalcoholic steatohepatitis (NASH) is one of the commonly diagnosed liver diseases. The disease is also known as silent liver disease. Fat deposition in liver, along with inflammation is one of the significant conditions that occurs during the disease. The surge in the incidence rate of nonalcoholic steatohepatitis has increased the demand for therapeutics to treat the disease. Consequently, multiple drugs are being launched. These drugs aim to provide relief from the disease.

According to market analysts, the global nonalcoholic steatohepatitis therapeutics market is anticipated to witness double digit growth in the next few years. Increase in awareness among people about therapeutics is also a major factor boosting the growth of the market in various regions across the world. However, poor diagnostics and lack of proper diagnostic technique are projected to restrain the global market in the next few years.

Rise in Investments in Drug Research and Development by Pharmaceutical Companies to Drive Global Market

Increase in research & development investments by pharmaceutical companies has led to seamless integration or multifunctional outsourcing solutions for drug research & development from the early development phase through the late-stage design phase. Outsourcing has grown as a strategic solution to offset the shortage of in-house resources necessary for product innovation, as pharma businesses face massive pressure to minimize operating expenses. Key pharmaceutical corporations are shifting to a simpler business strategy that primarily depends on outsourcing.

Majority of pharmaceutical companies outsource their testing facilities throughout research and development to increase profit margins, meet drug discovery timeframes, and save money.

Request a custom report on Nonalcoholic Steatohepatitis Therapeutics Market

Increase in Number of People with Diabetes and Obesity to Propel Global Market

The number of patients suffering from nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) is high across the globe. However, the number increases in developed economies such as North America. This provides significant opportunities to companies and research centers looking to invest in the market. Moreover, the number of children suffering from obesity has nearly tripled in the past few years. This requires urgent treatment methods to keep a check and cure the disease in its initial stages.

People in the U.S. also suffer from high cholesterol levels. There is no exact cure for the disease; however, treatment is still being developed and worked upon. Moreover, advancements in technology and continuous efforts by research firms to develop a more effective treatment method to drive the global nonalcoholic steatohepatitis therapeutics market.

Impact of COVID-19 on Global Nonalcoholic Steatohepatitis Therapeutics Market

The etiology of COVID-19 liver injury can be related to various reasons, including virus-induced inflammatory responses, hepatic obstruction, hypoxia, and drug-induced liver problems. Coronavirus has been linked to hepatic damage and liver-related fatality in cirrhotic individuals. The impact of COVID-19 on health services has had a negative influence on the care of delivery and the prognosis of patients with chronic liver disease. Consequently, there has been a drop in the therapy, detection, and follow-up of individuals with liver problems, which has had a severe effect on the healthcare industry. Additionally, drug clinical trials have stalled since most corporations have postponed the launch of newest studies in various nations.

Elafibranor Reduces Liver Fat, Gains Preference for Treatment of NASH

The global nonalcoholic steatohepatitis therapeutics market has been segmented based on drug type into potential phase III candidates obeticholic acid (OCA), Aramchol, Saroglitazar, and Elafibranor. Moreover, the report provides a list of candidates in phase I and phase II clinical trials. Elafibranor is expected to account for a key share of the global market during the forecast period, followed by Obeticholic Acid (OCA). The Elafibranor segment is expected to grow at the highest CAGR from 2022 to 2031.

Elafibranor has the capability to reduce fat substance of liver and has demonstrated positive impact during phase 3 clinical trials. This progress of the clinical trial has helped in the likelihood of commercialization of Elafibranor. Elafibranor has better prospects in the market, as there is no medicine available for the treatment of NASH.

Cost-cutting Pressure from Regulatory Bodies to Restrain Market Growth

Governments in both rich and emerging economies are advocating cost-cutting initiatives such as lowering prescription coverage costs and increasing the usage of generic medications. Governments, insurers, and individuals are putting substantial cost-cutting pressure on drug makers globally. This leads to increase in medication acceptance in developing countries, where there is a considerable need of low-cost treatments. This, however, has a negative effect on the performance of various pharmaceutical businesses. This trend is likely to continue during the forecast period, owing to the ongoing demand from insurers and lowering of pharma pricing by personal & corporate payers due to worries about providing more innovative drugs to treat prevalent ailments.

Regional Outlook of Global Nonalcoholic Steatohepatitis Therapeutics Market

In terms of region, the global nonalcoholic steatohepatitis therapeutics market has been segmented into North America, Asia Pacific, Europe, Latin America, Middle East & Africa. North America dominated the global market, accounting for key share in 2021.

North America is significantly affected by NASH due to rise in population suffering from diabetes and obesity. Moreover, prevailing cases of high cholesterol and changes in lifestyle make North America an attractive market for future development and growth.

In Europe, countries such as Italy, Spain, Germany, the U.K., and France are the main areas with high prevalence of NASH. These countries are likely to be highly lucrative markets for nonalcoholic steatohepatitis therapeutics.

Analysis of Key Players in Global Nonalcoholic Steatohepatitis Therapeutics Market

This report profiles key players in the global nonalcoholic steatohepatitis therapeutics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The global nonalcoholic steatohepatitis therapeutics market is highly fragmented, with the presence of a number of international as well as regional players. Leading players operating in the global nonalcoholic steatohepatitis therapeutics market are Intercept Pharmaceuticals, Inc., GENFIT SA, Zydus Cadila, Conatus Pharmaceuticals, and Tobira Therapeutics, Inc., AstraZeneca plc, Galmed Pharmaceuticals Ltd., Gilead Sciences, Inc., and Immuron Ltd., among others.

The report on the global nonalcoholic steatohepatitis therapeutics market discusses individual strategies, followed by company profiles of manufacturers of the nonalcoholic steatohepatitis therapeutics market products. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global nonalcoholic steatohepatitis therapeutics market.

Key Developments in Global Nonalcoholic Steatohepatitis Therapeutics Market

Key players in the global nonalcoholic steatohepatitis therapeutics market are growing their market presence by adopting various strategies such as mergers & acquisitions and research collaborations with other companies to launch innovative products and consolidate their market position across the world. Key developments in the global nonalcoholic steatohepatitis therapeutics market include:

  • In January 2019, Genfit took the first step toward making this test available, as it had signed a licensing agreement with LabCorp, the leading drug development and NASH clinical trial company, to expand the access to NIS4 in the global clinical research community

Global Nonalcoholic Steatohepatitis Therapeutics Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 10.1 Bn

Market Forecast Value in 2031

US$ 20.2 Bn

Growth Rate (CAGR)

13.6%

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Bn for Value

Market Analysis

It includes cross segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market Player - Competition Matrix (by tier and size of companies)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Drug Type
    • Obeticholic Acid (OCA)
    • Aramchol (Arachidyl Amido Cholanoic Acid)
    • Saroglitazar
    • Elafibranor

Regions Covered

  • North America
  • Latin America
  • Europe
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • AstraZeneca plc
  • Intercept Pharmaceuticals Inc.
  • Galmed Pharmaceuticals Ltd.
  • GENFIT SA
  • Gilead Sciences, Inc.
  • Zydus Cadila
  • Immuron Ltd.
  • Conatus Pharmaceuticals
  • Tobira Therapeutics, Inc.
  • Other prominent players

Customization Scope

Available upon request

Pricing

Available upon request

Interested in this report?
Get a FREE sample now!

Get Free Sample

*Get Sample Report (PDF) sent to your email within minutes

Frequently Asked Questions

How big was the global nonalcoholic steatohepatitis therapeutics market in 2021?

The global nonalcoholic steatohepatitis therapeutics market was valued at US$ 10.1 Bn in 2021.

How big will be the nonalcoholic steatohepatitis therapeutics market in 2031?

The global nonalcoholic steatohepatitis therapeutics market will surpass US$ 13.6 Bn by 2031.

What are the prominent trends impacting market growth?

Surge in number of nonalcoholic steatohepatitis incidence and increase in cases of diabetes & obesity propel demand and positively impact the global market.

Which region held key market share during the forecast period?

North America is expected to be a potential revenue generator for vendors during the forecast period.

Who are the prominent players in the global nonalcoholic steatohepatitis therapeutics market?

Prominent players in the global nonalcoholic steatohepatitis therapeutics market include Intercept Pharmaceuticals, Inc., GENFIT SA, Zydus Cadila, Conatus Pharmaceuticals, and Tobira Therapeutics, Inc., AstraZeneca plc, Galmed Pharmaceuticals Ltd., Gilead Sciences, Inc., and Immuron Ltd.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Nonalcoholic Steatohepatitis Therapeutics Market

4. Market Overview

    4.1. Introduction

        4.1.1. Drug Type Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Nonalcoholic Steatohepatitis Therapeutics Market Analysis and Forecast, 2017–2031

5. Key Insights

    5.1. Key Product/ Brand Analysis

    5.2. Key industry events (mergers, acquisitions, product launches etc.)

    5.3. Technological Advancements

    5.4. Regulatory Scenario, by Region/ Globally

    5.5. COVID-19 Pandemics Impact on Industry (value chain and short / mid / long term impact)

6. Global Nonalcoholic Steatohepatitis Therapeutics Market Analysis and Forecast, by Drug Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Drug Type, 2017–2031

        6.3.1. Obeticholic Acid (OCA)

        6.3.2. Aramchol (arachidyl amido cholanoic acid)

        6.3.3. Saroglitazar

        6.3.4. Elafibranor

    6.4. Market Attractiveness By Drug Type

7. Global Nonalcoholic Steatohepatitis Therapeutics Market Analysis and Forecast, by Region

    7.1. Key Findings

    7.2. Market Value Forecast, by Region

        7.2.1. North America

        7.2.2. Europe

        7.2.3. Asia Pacific

        7.2.4. Latin America

        7.2.5. Middle East & Africa

    7.3. Market Attractiveness Analysis, by Region

8. North America Nonalcoholic Steatohepatitis Therapeutics Market Analysis and Forecast

    8.1. Introduction

        8.1.1. Key Findings

    8.2. Market Value Forecast, by Drug Type, 2017–2031

        8.2.1. Obeticholic Acid (OCA)

        8.2.2. Aramchol (arachidyl amido cholanoic acid)

        8.2.3. Saroglitazar

        8.2.4. Elafibranor

    8.3. Market Value Forecast, by Country, 2017–2031

        8.3.1. U.S.

        8.3.2. Canada

    8.4. Market Attractiveness Analysis

        8.4.1. By Drug Type

        8.4.2. By Country

9. Europe Nonalcoholic Steatohepatitis Therapeutics Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. Market Value Forecast, by Drug Type, 2017–2031

        9.2.1. Obeticholic Acid (OCA)

        9.2.2. Aramchol (arachidyl amido cholanoic acid)

        9.2.3. Saroglitazar

        9.2.4. Elafibranor

    9.3. Market Value Forecast, by Country/Sub-region, 2017–2031

        9.3.1. Germany

        9.3.2. U.K.

        9.3.3. France

        9.3.4. Spain

        9.3.5. Italy

        9.3.6. Rest of Europe

    9.4. Market Attractiveness Analysis

        9.4.1. By Drug Type

        9.4.2. By Country/Sub-region

10. Asia Pacific Nonalcoholic Steatohepatitis Therapeutics Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Drug Type, 2017–2031

        10.2.1. Obeticholic Acid (OCA)

        10.2.2. Aramchol (arachidyl amido cholanoic acid)

        10.2.3. Saroglitazar

        10.2.4. Elafibranor

    10.3. Market Value Forecast, by Country/Sub-region, 2017–2031

        10.3.1. China

        10.3.2. Japan

        10.3.3. India

        10.3.4. Australia & New Zealand

        10.3.5. Rest of Asia Pacific

    10.4. Market Attractiveness Analysis

        10.4.1. By Drug Type

        10.4.2. By Country/Sub-region

11. Latin America Nonalcoholic Steatohepatitis Therapeutics Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Drug Type, 2017–2031

        11.2.1. Obeticholic Acid (OCA)

        11.2.2. Aramchol (arachidyl amido cholanoic acid)

        11.2.3. Saroglitazar

        11.2.4. Elafibranor

    11.3. Market Value Forecast, by Country/Sub-region, 2017–2031

        11.3.1. Brazil

        11.3.2. Mexico

        11.3.3. Rest of Latin America

    11.4. Market Attractiveness Analysis

        11.4.1. By Drug Type

        11.4.2. By Country/Sub-region

12. Middle East & Africa Nonalcoholic Steatohepatitis Therapeutics Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Drug Type, 2017–2031

        12.2.1. Obeticholic Acid (OCA)

        12.2.2. Aramchol (arachidyl amido cholanoic acid)

        12.2.3. Saroglitazar

        12.2.4. Elafibranor

    12.3. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.3.1. GCC Countries

        12.3.2. South Africa

        12.3.3. Rest of Middle East & Africa

    12.4. Market Attractiveness Analysis

        12.4.1. By Drug Type

        12.4.2. By Country/Sub-region

13. Competition Landscape

    13.1. Market Player - Competition Matrix (by tier and size of companies)

    13.2. Market Share Analysis By Company (2021)

    13.3. Company Profiles

        13.3.1. F. Hoffmann-La Roche

            13.3.1.1. Company Overview (HQ, Business Segments, Employee)

            13.3.1.2. Product Portfolio

            13.3.1.3. SWOT Analysis

            13.3.1.4. Strategic Overview

        13.3.2. Siemens Healthineers AG.

            13.3.2.1. Company Overview (HQ, Business Segments, Employee)

            13.3.2.2. Product Portfolio

            13.3.2.3. SWOT Analysis

            13.3.2.4. Strategic Overview

        13.3.3. Thermo Fisher Scientific

            13.3.3.1. Company Overview (HQ, Business Segments, Employee)

            13.3.3.2. Product Portfolio

            13.3.3.3. SWOT Analysis

            13.3.3.4. Strategic Overview

        13.3.4. Danaher Corporation

            13.3.4.1. Company Overview (HQ, Business Segments, Employee)

            13.3.4.2. Product Portfolio

            13.3.4.3. SWOT Analysis

            13.3.4.4. Strategic Overview

        13.3.5. Bio-Rad Laboratories

            13.3.5.1. Company Overview (HQ, Business Segments, Employee)

            13.3.5.2. Product Portfolio

            13.3.5.3. SWOT Analysis

            13.3.5.4. Strategic Overview

        13.3.6. Abbott Laboratories

            13.3.6.1. Company Overview (HQ, Business Segments, Employee)

            13.3.6.2. Product Portfolio

            13.3.6.3. SWOT Analysis

            13.3.6.4. Strategic Overview

        13.3.7. Alpco

            13.3.7.1. Company Overview (HQ, Business Segments, Employee)

            13.3.7.2. Product Portfolio

            13.3.7.3. SWOT Analysis

            13.3.7.4. Strategic Overview

        13.3.8. Beckman Coulter Inc.

            13.3.8.1. Company Overview (HQ, Business Segments, Employee)

            13.3.8.2. Product Portfolio

            13.3.8.3. SWOT Analysis

            13.3.8.4. Strategic Overview

        13.3.9. Chromsystems Instrume

            13.3.9.1. Company Overview (HQ, Business Segments, Employee)

            13.3.9.2. Product Portfolio

            13.3.9.3. SWOT Analysis

            13.3.9.4. Strategic Overview

        13.3.10. Pharmaceutical Drug Type Development LLC

            13.3.10.1. Company Overview (HQ, Business Segments, Employee)

            13.3.10.2. Product Portfolio

            13.3.10.3. SWOT Analysis

            13.3.10.4. Strategic Overview

        13.3.11. Randox Laboratories Ltd.

            13.3.11.1. Company Overview (HQ, Business Segments, Employee)

            13.3.11.2. Product Portfolio

            13.3.11.3. SWOT Analysis

            13.3.11.4. Strategic Overview

        13.3.12. Other prominent players

            13.3.12.1. Company Overview (HQ, Business Segments, Employee)

            13.3.12.2. Product Portfolio

            13.3.12.3. SWOT Analysis

            13.3.12.4. Strategic Overview

List of Tables

Table 01: Global Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017-2031

Table 02: Global Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Region, 2017-2031

Table 03: North America Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country, 2017-2031

Table 04: North America Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031

Table 05: Europe Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017-2031

Table 06: Europe Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031

Table 07: Asia Pacific Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017-2031

Table 08: Asia Pacific Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031

Table 09: Latin America Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017-2031

Table 10: Latin America Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031

Table 11: Middle East & Africa Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017-2031

Table 12: Middle East & Africa Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031

List of Figures

Figure 01: Global Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017-2031

Figure 02: Global Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Region, 2017-2031

Figure 03: North America Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country, 2017-2031

Figure 04: North America Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031

Figure 05: Europe Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017-2031

Figure 06: Europe Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031

Figure 07: Asia Pacific Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017-2031

Figure 08: Asia Pacific Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031

Figure 09: Latin America Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017-2031

Figure 10: Latin America Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031

Figure 11: Middle East & Africa Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2017-2031

Figure 12: Middle East & Africa Nonalcoholic Steatohepatitis Therapeutics Market Size (US$ Mn) and Forecast, by Drug Type, 2017-2031

Figure 13: Global Nonalcoholic Steatohepatitis Therapeutics Market Share Analysis, by Company (2021)

Transparency Market Research Plus

Get a free copy if the report you purchased is updated within 90 days

Copyright © Transparency Market Research, Inc. All Rights reserved